Literature DB >> 34239808

Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update.

Masatoshi Kudo1, Yusuke Kawamura2, Kiyoshi Hasegawa3, Ryosuke Tateishi4, Kazuya Kariyama5, Shuichiro Shiina6, Hidenori Toyoda7, Yasuharu Imai8, Atsushi Hiraoka9, Masafumi Ikeda10, Namiki Izumi11, Michihisa Moriguchi12, Sadahisa Ogasawara13, Yasunori Minami1, Kazuomi Ueshima1, Takamichi Murakami14, Shiro Miyayama15, Osamu Nakashima16, Hirohisa Yano17, Michiie Sakamoto18, Etsuro Hatano19, Mitsuo Shimada20, Norihiro Kokudo21, Satoshi Mochida22, Tetsuo Takehara23.   

Abstract

The Clinical Practice Manual for Hepatocellular Carcinoma was published based on evidence confirmed by the Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma along with consensus opinion among a Japan Society of Hepatology (JSH) expert panel on hepatocellular carcinoma (HCC). Since the JSH Clinical Practice Guidelines are based on original articles with extremely high levels of evidence, expert opinions on HCC management in clinical practice or consensus on newly developed treatments are not included. However, the practice manual incorporates the literature based on clinical data, expert opinion, and real-world clinical practice currently conducted in Japan to facilitate its use by clinicians. Alongside each revision of the JSH Guidelines, we issued an update to the manual, with the first edition of the manual published in 2007, the second edition in 2010, the third edition in 2015, and the fourth edition in 2020, which includes the 2017 edition of the JSH Guideline. This article is an excerpt from the fourth edition of the HCC Clinical Practice Manual focusing on pathology, diagnosis, and treatment of HCC. It is designed as a practical manual different from the latest version of the JSH Clinical Practice Guidelines. This practice manual was written by an expert panel from the JSH, with emphasis on the consensus statements and recommendations for the management of HCC proposed by the JSH expert panel. In this article, we included newly developed clinical practices that are relatively common among Japanese experts in this field, although all of their statements are not associated with a high level of evidence, but these practices are likely to be incorporated into guidelines in the future. To write this article, coauthors from different institutions drafted the content and then critically reviewed each other's work. The revised content was then critically reviewed by the Board of Directors and the Planning and Public Relations Committee of JSH before publication to confirm the consensus statements and recommendations. The consensus statements and recommendations presented in this report represent measures actually being conducted at the highest-level HCC treatment centers in Japan. We hope this article provides insight into the actual situation of HCC practice in Japan, thereby affecting the global practice pattern in the management of HCC.
Copyright © 2021 by S. Karger AG, Basel.

Entities:  

Keywords:  Consensus statement; Diagnosis; Hepatocellular carcinoma; Japan Society of Hepatology; Pathology; Treatment

Year:  2021        PMID: 34239808      PMCID: PMC8237791          DOI: 10.1159/000514174

Source DB:  PubMed          Journal:  Liver Cancer        ISSN: 1664-5553            Impact factor:   11.740


  41 in total

1.  Efficacy and safety of regorafenib in Japanese patients with advanced gastrointestinal stromal tumors.

Authors:  Ryugo Teranishi; Tsuyoshi Takahashi; Toshirou Nishida; Seiichi Hirota; Yukinori Kurokawa; Takuro Saito; Kazuyoshi Yamamoto; Kotaro Yamashita; Koji Tanaka; Tomoki Makino; Masaaki Motoori; Takeshi Omori; Kiyokazu Nakajima; Hidetoshi Eguchi; Yuichiro Doki
Journal:  Int J Clin Oncol       Date:  2022-04-18       Impact factor: 3.402

2.  Newly Developed Modified ALBI Grade Shows Better Prognostic and Predictive Value for Hepatocellular Carcinoma.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2021-12-08       Impact factor: 11.740

3.  Simple Scoring System for Predicting TACE Unsuitable among Intermediate-Stage Hepatocellular Carcinoma Patients in the Multiple Systemic Treatment Era.

Authors:  Atsushi Hiraoka; Takashi Kumada; Kazuya Kariyama; Hidenori Toyoda; Satoshi Yasuda; Kunihiko Tsuji; Takeshi Hatanaka; Satoru Kakizaki; Atsushi Naganuma; Toru Ishikawa; Toshifumi Tada; Koichi Takaguchi; Ei Itobayashi; Noritomo Shimada; Hiroshi Shibata; Takaaki Tanaka; Akemi Tsutsui; Takuya Nagano; Michitaka Imai; Shinichiro Nakamura; Kazuhiro Nouso
Journal:  Oncology       Date:  2021-11-29       Impact factor: 2.935

4.  A case of hepatocellular carcinoma with long-term survival by multidisciplinary treatment for cranial and skeletal muscle metastases.

Authors:  Noriyuki Akutsu; Yujiro Kawakami; Yasunao Numata; Takehiro Hirano; Kohei Wagatsuma; Keisuke Ishigami; Shigeru Sasaki; Hiroshi Nakase
Journal:  Clin J Gastroenterol       Date:  2022-07-14

Review 5.  Management of Systemic Therapies and Hepatic Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma Based on Sarcopenia Assessment.

Authors:  Takahiro Yamasaki; Issei Saeki; Yurika Yamauchi; Toshihiko Matsumoto; Yutaka Suehiro; Tomokazu Kawaoka; Shinsuke Uchikawa; Akira Hiramatsu; Hiroshi Aikata; Kazufumi Kobayashi; Takayuki Kondo; Sadahisa Ogasawara; Tetsuhiro Chiba; Taro Takami; Kazuaki Chayama; Naoya Kato; Isao Sakaida
Journal:  Liver Cancer       Date:  2022-02-22       Impact factor: 12.430

6.  Efficacy and Safety of Lenvatinib Combined With PD-1 Inhibitors Plus TACE for Unresectable Hepatocellular Carcinoma Patients in China Real-World.

Authors:  Xiaowei Li; Zhigang Fu; Xiaoxia Chen; Kunkun Cao; Jiaming Zhong; Li Liu; Ning Ding; Xiaoli Zhang; Jian Zhai; Zengqiang Qu
Journal:  Front Oncol       Date:  2022-07-04       Impact factor: 5.738

7.  Lenvatinib with or without Concurrent Drug-Eluting Beads Transarterial Chemoembolization in Patients with Unresectable, Advanced Hepatocellular Carcinoma: A Real-World, Multicenter, Retrospective Study.

Authors:  Dongdong Xia; Wei Bai; Enxin Wang; Jiaping Li; Xiaoming Chen; Zhexuan Wang; Mingsheng Huang; Ming Huang; Junhui Sun; Weizhu Yang; Zhengyu Lin; Jianbing Wu; Zixiang Li; Shufa Yang; Xu Zhu; Zaizhong Chen; Yanfang Zhang; Wenzhe Fan; Qicong Mai; Rong Ding; Chunhui Nie; Long Feng; Xueda Li; Wukui Huang; Jun Sun; Qiuhe Wang; Yong Lv; Xiaomei Li; Bohan Luo; Zhengyu Wang; Jie Yuan; Wengang Guo; Kai Li; Bing Li; Ruijun Li; Zhanxin Yin; Jielai Xia; Guohong Han
Journal:  Liver Cancer       Date:  2022-03-09       Impact factor: 12.430

8.  Deep Learning for Approaching Hepatocellular Carcinoma Ultrasound Screening Dilemma: Identification of α-Fetoprotein-Negative Hepatocellular Carcinoma From Focal Liver Lesion Found in High-Risk Patients.

Authors:  Wei-Bin Zhang; Si-Ze Hou; Yan-Ling Chen; Feng Mao; Yi Dong; Jian-Gang Chen; Wen-Ping Wang
Journal:  Front Oncol       Date:  2022-05-26       Impact factor: 5.738

9.  A Novel Treatment Strategy for Patients with Intermediate-Stage HCC Who Are Not Suitable for TACE: Upfront Systemic Therapy Followed by Curative Conversion.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2021-10-12       Impact factor: 11.740

Review 10.  New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma.

Authors:  Masatoshi Kudo
Journal:  Int J Clin Oncol       Date:  2022-05-08       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.